Drug intelligence / Profile preview

belantamab + belantamab mafodotin + pomalidomide + dexamethasone

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

unconjugated belantamab + pomalidomide + dexamethasone + Blenrep is an investigational combination regimen developed by GSK for the treatment of relapsed/refractory multiple myeloma. This four-drug regimen combines two anti-BCMA (B-cell maturation antigen) agents—the unconjugated (naked) monoclonal antibody belantamab and the antibody-drug conjugate (ADC) belantamab mafodotin (Blenrep)—with the immunomodulatory agent pomalidomide and the corticosteroid dexamethasone. The rationale behind this combination is to enhance anti-myeloma activity by utilizing both the direct cytotoxicity of the ADC's auristatin F payload and the immune-mediated effects of the naked antibody and pomalidomide. The regimen is currently being evaluated in the DREAMM-5 platform trial (NCT04091126), specifically in Part 3, to determine if the addition of the unconjugated antibody to the standard-of-care backbone can improve clinical outcomes in patients who have received prior therapies.

Brand names: Blenrep
Other names: unconjugated belantamab + pomalidomide + dexamethasone + Blenrep

Targets

MicrotubuleBCMA (B-cell maturation antigen)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)GR (Glucocorticoid receptor)CRBN (Cereblon)

Beyond the preview

Go deeper on belantamab + belantamab mafodotin + pomalidomide + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on belantamab + belantamab mafodotin + pomalidomide + dexamethasone.

Explore the full profile